Amicus Therapeutics (FOLD) Stock Price Down 5.2%
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) fell 5.2% during mid-day trading on Thursday . The company traded as low as $10.82 and last traded at $10.82. 2,374,005 shares were traded during trading, a decline of 11% from the average session volume of 2,662,283 shares. The stock had previously closed at $11.41.
A number of brokerages have recently issued reports on FOLD. BidaskClub raised shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 6th. Chardan Capital downgraded shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $18.00 to $15.00 in a report on Friday, August 17th. Citigroup began coverage on shares of Amicus Therapeutics in a report on Monday, October 29th. They set a “neutral” rating and a $12.00 price target on the stock. Cowen reaffirmed a “buy” rating and set a $31.00 price target on shares of Amicus Therapeutics in a report on Friday, October 12th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Amicus Therapeutics presently has an average rating of “Buy” and an average target price of $19.50.
The company has a debt-to-equity ratio of 0.78, a quick ratio of 10.73 and a current ratio of 9.12. The firm has a market cap of $2.16 billion, a PE ratio of -3.63 and a beta of 1.48.
In related news, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $12.23, for a total value of $122,300.00. Following the transaction, the chief financial officer now owns 127,622 shares of the company’s stock, valued at $1,560,817.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive acquired 50,000 shares of the company’s stock in a transaction that occurred on Friday, September 21st. The stock was acquired at an average cost of $12.53 per share, for a total transaction of $626,500.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 620,000 shares of company stock worth $7,505,000. 2.90% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Exane Derivatives purchased a new position in shares of Amicus Therapeutics in the second quarter worth approximately $137,000. Arbor Wealth Management LLC purchased a new position in shares of Amicus Therapeutics in the second quarter worth approximately $144,000. P.R. Herzig & Co. Inc. purchased a new position in shares of Amicus Therapeutics in the second quarter worth approximately $156,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Amicus Therapeutics in the second quarter worth approximately $179,000. Finally, TCW Group Inc. purchased a new position in shares of Amicus Therapeutics in the second quarter worth approximately $245,000.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/10/amicus-therapeutics-fold-stock-price-down-5-2.html.
Amicus Therapeutics Company Profile (NASDAQ:FOLD)
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
See Also: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.